Baker McKenzie has acted for CLSA and other underwriters in connection with Joincare Pharmaceutical Group Industry, on global depositary receipts listing on the SIX Swiss Exchange. This transactions proves that the China-Switzerland Stock Connect has
Tags :Jan Lusti
Baker McKenzie has advised Leonteq Securities regarding its new cooperation with VP Bank for the manufacturing and distribution of structured investment products under a newly-created innovative white-labelling issuance model. As part of this cooperation, VP
Baker McKenzie Switzerland, along with lawyers from the London and Amsterdam office, has advised Zur Rose Group on the placement of convertible bonds due 2026 and a capital increase through an accelerated bookbuilding (“ABB“) process. Zur
Baker McKenzie has acted as legal advisor on the successful offering and listings of Global Depositary Receipts (GDR) on SIX Swiss Exchange of four Chinese companies: GEM Co., Gotion High-tech Co., Keda Industrial Group Co.,
Baker McKenzie Switzerland, along with other Baker McKenzie offices, advised Feintool International Holding (“Feintool”) on its capital increase by approximately CHF 202 million via a rights offering. UBS acted as sole global coordinator and bookrunner while
Helveteq, a Swiss issuer of ESG-transparent investment products, is launching a carbon neutral crypto ETPs, a solution for climate-neutral blockchain investments, as a new Swiss ETP issuer. Helveteq along with Swiss FinTech Innovation Lab of
Arsenal Capital Partners, a global private equity firm focusing on franchises in the healthcare and industrial sectors, has completes its acquisition of ATP Group from Bregal Unternehmerkapital. Swiss headquartered ATP Group is a manufacturer of
The first Swiss SPAC, VT5 Acquisition Company, successfully priced its initial public offering. The listing of the Class A Shares and Redeemable Warrants on
Novartis has entered into an agreement to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a consideration of USD 20.7 billion. Novartis had acquired the stake between 2001 and 2003 for approximately USD 5
Santhera Pharmaceuticals Holding announced the closing of the first tranche of its financing arrangement with a fund managed by Highbridge Capital Management. The team was led by partner Matthias Courvoisier (Capital Markets) and senior associate
